Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
KARD
Kardigan
$13.46
-11.7%
$19.09
$12.52
▼
$27.00
$1.26BN/A502,361 shs1.36 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$187.52
-7.7%
$128.42
$22.28
▼
$212.22
$74.86B1.0912.00 million shs16.80 million shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.05
+0.5%
$1.22
$0.97
▼
$2.73
$354.37M2.277.18 million shs4.59 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.48
+0.3%
$27.46
$23.62
▼
$29.21
$156.63B0.3240.54 million shs16.58 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
KARD
Kardigan
+3.04%+3.11%-26.91%-36.05%+1,523,999,900.00%
Moderna, Inc. stock logo
MRNA
Moderna
+6.95%+3.01%+39.62%+154.74%+613.27%
Ocugen, Inc. stock logo
OCGN
Ocugen
+1.96%0.00%-23.53%-30.67%-41.24%
Pfizer Inc. stock logo
PFE
Pfizer
-1.41%-4.66%-3.54%+14.05%+0.18%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
KARD
Kardigan
$13.46
-11.7%
$19.09
$12.52
▼
$27.00
$1.26BN/A502,361 shs1.36 million shs
Moderna, Inc. stock logo
MRNA
Moderna
$187.52
-7.7%
$128.42
$22.28
▼
$212.22
$74.86B1.0912.00 million shs16.80 million shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$1.05
+0.5%
$1.22
$0.97
▼
$2.73
$354.37M2.277.18 million shs4.59 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$27.48
+0.3%
$27.46
$23.62
▼
$29.21
$156.63B0.3240.54 million shs16.58 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
KARD
Kardigan
+3.04%+3.11%-26.91%-36.05%+1,523,999,900.00%
Moderna, Inc. stock logo
MRNA
Moderna
+6.95%+3.01%+39.62%+154.74%+613.27%
Ocugen, Inc. stock logo
OCGN
Ocugen
+1.96%0.00%-23.53%-30.67%-41.24%
Pfizer Inc. stock logo
PFE
Pfizer
-1.41%-4.66%-3.54%+14.05%+0.18%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
KARD
Kardigan
2.50
Moderate Buy$42.25213.89% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.08
Hold$77.83-58.49% Downside
Ocugen, Inc. stock logo
OCGN
Ocugen
2.60
Moderate Buy$9.50809.09% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.19
Hold$28.563.91% Upside

Current Analyst Ratings Breakdown

Latest OCGN, MRNA, PFE, and KARD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/6/2026
Pfizer Inc. stock logo
PFE
Pfizer
Set Price TargetOutperform$33.00
9/30/2026
Moderna, Inc. stock logo
MRNA
Moderna
DowngradeNeutral ➝ Sell$60.00 ➝ $80.00
9/25/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingMarket Perform
9/23/2026
Moderna, Inc. stock logo
MRNA
Moderna
UpgradeHold
9/22/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingNeutral
9/14/2026
KARD
Kardigan
Initiated CoverageSell (D)
9/10/2026
Pfizer Inc. stock logo
PFE
Pfizer
Boost Price TargetHold$28.00 ➝ $30.00
9/9/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingSell (D-)
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
Set Price Target$81.00
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
DowngradeHold ➝ Sell
9/3/2026
Moderna, Inc. stock logo
MRNA
Moderna
DowngradeNeutral ➝ Sell$40.00 ➝ $81.00
(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
KARD
Kardigan
N/AN/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
$2.21B33.88N/AN/A$22.14 per share8.47
Ocugen, Inc. stock logo
OCGN
Ocugen
$4.58M77.36N/AN/A($0.04) per share-26.13
Pfizer Inc. stock logo
PFE
Pfizer
$62.58B2.50$4.35 per share6.32$15.26 per share1.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
KARD
Kardigan
-$191.94MN/AN/AN/AN/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$7.99N/AN/AN/A-141.43%-28.30%-19.39%11/5/2026 (Estimated)
Ocugen, Inc. stock logo
OCGN
Ocugen
-$67.85M-$0.26N/AN/AN/AN/A-127,987.80%-115.95%11/4/2026 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$7.77B$0.7636.169.321.876.80%19.63%8.46%11/3/2026 (Estimated)

Latest OCGN, MRNA, PFE, and KARD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/3/2026Q3 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.7590N/AN/AN/A$15.93 billionN/A
8/11/2026Q2 2026
KARD
Kardigan
N/A-$4.61N/A-$4.61N/AN/A
8/6/2026Q2 2026
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.0533-$0.07-$0.0167-$0.07$0.89 million$1.49 million
8/4/2026Q2 2026
Pfizer Inc. stock logo
PFE
Pfizer
$0.6820$0.77+$0.0880-$0.04$14.40 billion$15.03 billion
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.03-$1.97+$0.06-$1.97$102.93 million$145.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
KARD
Kardigan
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A
Pfizer Inc. stock logo
PFE
Pfizer
$1.726.26%-13.20%226.32%16 Years
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
KARD
Kardigan
N/A
8.72
8.72
Moderna, Inc. stock logo
MRNA
Moderna
0.09
2.29
2.18
Ocugen, Inc. stock logo
OCGN
Ocugen
4.17
0.80
0.80
Pfizer Inc. stock logo
PFE
Pfizer
0.71
1.27
0.96

Institutional Ownership

CompanyInstitutional Ownership
KARD
Kardigan
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%

Insider Ownership

CompanyInsider Ownership
KARD
Kardigan
N/A
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Ocugen, Inc. stock logo
OCGN
Ocugen
3.95%
Pfizer Inc. stock logo
PFE
Pfizer
0.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
KARD
Kardigan
24193.50 millionN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
4,700399.24 million356.12 millionOptionable
Ocugen, Inc. stock logo
OCGN
Ocugen
116339.11 million325.72 millionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
75,0005.70 billion5.66 billionOptionable

Recent News About These Companies

Pfizer Declares Fourth-Quarter 2026 Dividend
PFE vs. JNJ: Which Stock Is the Better Value Option?
Are Investors Undervaluing Pfizer (PFE) Right Now?
Pfizer (NYSE:PFE) Stock Price Down 1.4% - What's Next?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines

Kardigan NASDAQ:KARD

$13.46 -1.78 (-11.68%)
As of 03:46 PM Eastern

Kardigan Inc. is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc. is based in South San Francisco, California.

Moderna stock logo

Moderna NASDAQ:MRNA

$187.52 -15.69 (-7.72%)
Closing price 03:59 PM Eastern
Extended Trading
$187.46 -0.06 (-0.03%)
As of 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Ocugen stock logo

Ocugen NASDAQ:OCGN

$1.04 +0.01 (+0.48%)
Closing price 03:59 PM Eastern
Extended Trading
$1.05 +0.01 (+0.48%)
As of 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Pfizer stock logo

Pfizer NYSE:PFE

$27.48 +0.07 (+0.26%)
Closing price 03:59 PM Eastern
Extended Trading
$27.48 +0.00 (+0.02%)
As of 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.